最適治療を極める！　クローン病

出版社： 医学と看護社
著者：
発行日： 2019-07-20
分野： 臨床医学：内科  >  消化器一般
ISBN： 9784909888044
電子書籍版： 2019-07-20 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：約3営業日

3,300 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

3,300 円(税込)

購入する

商品紹介

患者の病態の理解と最適な治療を極める、好評の「潰瘍性大腸炎」に継ぐ姉妹編！

目次

  • 第１章　クローン病概念の成立と歴史的背景
    　１．クローン病の歴史を知る─クローン病の由来は雑誌の投稿規定のいたずら？
    　２．論文発表後の歴史
    　３．第二次世界大戦後の科学的・治療的進歩
    　４．治療の変遷

    第２章　クローン病の病態
    　１．遺伝的素因：感受性遺伝子の問題
    　２．環境因子：腸内細菌の役割
    　３．腸バリア：上皮と自然免疫
    　４．獲得免疫反応：エフェクター細胞と制御性T細胞

    第３章　クローン病の診断
    　１．潰瘍性大腸炎とクローン病との違いについて
    　２．クローン病の小腸・大腸内視鏡所見・治療のポイントとは？

    　３．クローン病の診断基準
    第４章 クローン病の治療
    　１．治療のポイント
    　２．栄養療法
    　　１）クローン病における栄養障害
    　　２）栄養療法
    　３．薬剤治療
    　　１）5-ASA製剤について
    　　２）ステロイド剤
    　　３）チオプリン製剤
    　　４）抗TNF-α抗体製剤
    　　５）Ustekinumab
    　　６）Vedolizumab
    　　７）Janus kinase（JAK）inhibitor

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 クローン病概念の成立と歴史的背景

P.13 掲載の参考文献
1) Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis : a pathologic and clinical entity. J Am Med Assoc. 1932 ; 99 : 1323-9.
 
2) Morgagni GB. Seat and Causes of Diseases. New York : Hafner Publishing. ; 1960 : 64-6 [Book 111, Letter XXXI, Article 2].
 
3) Dalziel TK. Chronic interstitial enteritis. Br Med J. 1913 ; 2 : 1068-70.
 
4) Ginzburg L. Regional enteritis : historical perspective. Gastroenterology. 1986 ; 90 : 1310-1.
PubMed
5) Franklin RH, Taylor S. Nonspecific granulomatous (regional) esophagitis. J Thorac Surg. 1950 ; 19 : 292-7.
 
6) Ross JR. Cicatrizing enteritis, colitis and gastritis ; a case report. Gastroenterology. 1949 ; 13 : 344-50.
PubMed
7) Gottlieb C, Alpert S. Regional jejunitis. Am J Roentgenol Radium Ther Nucl Med. 1937 ; 38 : 881-3.
 
8) Wells C. Ulcerative colitis and Crohn's disease. Ann R Coll Surg Engl. 1952 ; 11 : 105-20.
PubMed
9) Hughes CW, Baugh JH, Mologne LA, et al. A review of the late General Eisenhower's operations : epilog to a footnote to history. Ann Surg. 1971 ; 173 : 793-9.
 
10) Heaton LD, Ravdin IS, Blades B, et al. President Eisenhower's operation for regional enteritis : a footnote to history. Ann Surg. 1964 ; 159 : 661-6.
 
11) Lockhart-Mummery HE, Morson BC. Crohn's disease (regional enteritis) of the large intestine and its distinction from ulcerative colitis. Gut. 1960 ; 1 : 87-105.
PubMed
12) Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005 ; 308 : 385-9.
PubMed
13) Vora P, Shih DQ, McGovern DP, et al. Current concepts on the immunopathogenesis of inflammatory bowel disease. Front Biosci. 2012 ; 4 : 1451-77.
PubMed
14) Rivas MA, Beaudoin M, Gardet A, et al. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat Genet. 2011 ; 43 : 1066-73.
PubMed
15) Blonski W, Buchner AM, Lichtenstein GR. Inflammatory bowel disease therapy : current state-of-the-art. Curr Opin Gastroenterol. 2011 ; 27 : 346-57.
PubMed

第2章 クローン病の病態

P.25 掲載の参考文献
1) Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007 ; 448 : 427-34.
PubMed
2) Spehlmann ME, Begun AZ, Burghardt J, et al. Epidemiology of inflammatory bowel disease in a German twin cohort : results of a nationwide study. Inflamm Bowel Dis. 2008 ; 14 : 968-76.
 
3) Khor B, Gardet A, Xavier RJ. Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011 ; 474 : 307-17.
PubMed
4) Worthey EA, Mayer AN, Syverson GD, et al. Making a definitive diagnosis : successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011 ; 13 : 255-62.
 
5) Krieg A, Correa RG, Garrison JB, et al. XIAP mediates NOD signaling via interaction with RIP2. Proc Natl Acad Sci U S A. 2009 ; 106 : 14524-9.
PubMed
6) Glocker EO, Kotlarz D, Boztug K, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009 ; 361 : 2033-45.
PubMed
7) Uhlig HH. Monogenic diseases associated with intestinal inflammation : implications for the understanding of inflammatory bowel disease. Gut. 2013 ; 62 : 1795-805.
PubMed
8) McGovern DP, Kugathasan S, Cho JH. Genetics of inflammatory bowel diseases. Gastroenterology. 2015 ; 149 : 1163-76.e2.
 
9) Liu JZ, van Sommeren S, Huang H, et al. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet. 2015 ; 47 : 979-86.
PubMed
10) Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012 ; 491 : 119-24.
PubMed
11) Shaw MH, Kamada N, Warner N, et al. The ever-expanding function of NOD2 : autophagy, viral recognition, and T cell activation. Trends Immunol. 2011 ; 32 : 73-9.
 
12) Kuballa P, Huett A, Rioux JD, et al. Impaired autophagy of an intracellular pathogen induced by a Crohn's diseaseassociated ATG16L1 variant. PLoS One. 2008 ; 3 : e3391.
 
13) Travassos LH, Carneiro LA, Ramjeet M, et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membraneat the site of bacterial entry. Nat Immunol. 2010 ; 11 : 55-62.
PubMed
14) Cooney R, Baker J, Brain O, et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med. 2010 ; 16 : 90-7.
PubMed
15) Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006 ; 314 : 1461-3.
PubMed
16) Sandborn WJ, Feagan BG, Fedorak RN, et al ; Ustekinumab Crohn's Disease Study Group. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008 ; 135 : 1130-41.
 
17) Allais L, Kerckhof FM, Verschuere S, et al. Chronic cigarette smoke exposure induces microbial and inflammatory shifts and mucin changes in the murine gut. Environ Microbiol. 2016 ; 18 : 1352-63.
PubMed
18) Monick MM, Powers LS, Walters K, et al. Identification of an autophagy defect in smokers' alveolar macrophages. J Immunol. 2010 ; 185 : 5425-35.
PubMed
19) Sher ME, Bank S, Greenberg R, et al. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease. Inflamm Bowel Dis. 1999 ; 5 : 73-8.
PubMed
20) Hou JK, Abraham B, El-Serag H. Dietary intake and risk ofdeveloping inflammatory bowel disease : a systematic review of the literature. Am J Gastroenterol. 2011 ; 106 : 563-73.
 
21) Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis : a prospective cohort study. Gut. 2004 ; 53 : 1479-84.
PubMed
22) Ananthakrishnan AN, Khalili H, Konijeti GG, et al. Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut. 2014 ; 63 : 776-84.
PubMed
23) Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology. 2013 ; 145 : 970-7.
PubMed
24) Shaw SY, Blanchard JF, 24 Bernstein CN. Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol. 2010 ; 105 : 2687-92.
 
25) Selby W, Pavli P, Crotty B, et al ; Antibiotics in Crohn's Disease Study Group. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology. 2007 ; 132 : 2313-9.
 
26) Khalili H, Higuchi LM, Ananthakrishnan AN, et al. Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut. 2013 ; 62 : 1153-9.
PubMed
27) Ananthakrishnan AN, Higuchi LM, Huang ES, et al. Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis : a cohort study. Ann Intern Med. 2012 ; 156 : 350-9.
PubMed
28) Kvasnovsky CL, Aujla U, Bjarnason I. Nonsteroidal anti-inflammatory drugs and exacerbations of inflammatory bowel disease. Scand J Gastroenterol. 2015 ; 50 : 255-63.
PubMed
29) Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018 ; 11 : 1-10.
PubMed
30) Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013 ; 500 : 232-6.
PubMed
31) Varela E, Manichanh C, Gallart M, et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis. Aliment Pharmacol Ther. 2013 ; 38 : 151-61.
PubMed
32) Fujimoto T, Imaeda H, Takahashi K, et al. Decreased abundance of Faecalibacterium prausnitzii in the gut microbiota of Crohn's disease. J Gastroenterol Hepatol. 2013 ; 28 : 613-9.
PubMed
33) Takahashi K, Nishida A, Fujimoto T, et al. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn's disease [published correction appears in Digestion. 2016 ; 93 (2) : 174]. Digestion. 2016 ; 93 : 59-65.
 
34) Png CW, Linden SK, Gilshenan KS, et al. Mucolytic bacteria with increased prevalence in IBD mucosa augment in vitro utilization of mucin by other bacteria. Am J Gastroenterol.2010 ; 105 : 2420-8.
PubMed
35) Muise AM, Walters TD, Glowacka WK, et al. Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn's disease. Gut. 2009 ; 58 : 1121-7.
 
36) Gassler N, Rohr C, Schneider A, et al. Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol. 2001 ; 281 : G216-8.
PubMed
37) van der Flier LG, Clevers H. Stem cells, self-renewal, and differentiation in the intestinal epithelium. Annu Rev Physiol. 2009 ; 71 : 241-60.
PubMed
38) Herbert DR, Yang JQ, Hogan SP, et al. Intestinal epithelial cell secretion of RELM-b protects against gastrointestinal worm infection. J Exp Med. 2009 ; 206 : 2947-57.
PubMed
39) Itoh H, Beck PL, Inoue N, et al. A paradoxical reduction in susceptibility to colonic injury upon targeted transgenic ablation of goblet cells. J Clin Invest. 1999 ; 104 : 1539-47.
 
40) Salzman NH, Underwood MA, Bevins CL. Paneth cells, defensins, and the commensal microbiota : a hypothesis on intimate interplay at the intestinal mucosa. Semin Immunol. 2007 ; 19 : 70-83.
 
41) Fritz T, Niederreiter L, Adolph T, et al. Crohn's disease : NOD2, autophagy and ER stress converge. Gut. 2011 ; 60 : 1580-8.
PubMed
42) Smythies LE, Sellers M, Clements RH, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest. 2005 ; 115 : 66-75.
PubMed
43) Smith PD, Ochsenbauer-Jambor C, Smythies LE. Intestinal macrophages : unique effector cells of the innate immune system. Immunol Rev. 2005 ; 206 : 149-59.
PubMed
44) Denning TL, Wang YC, Patel SR, et al. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol. 2007 ; 8 : 1086-94.
PubMed
45) Smith AM, Rahman FZ, Hayee B, et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn's disease [published correction appears in J Exp Med. 2009 ; 206 (10) : 2301]. J Exp Med. 2009 ; 206 : 1883-97.
 
46) Kamada N, Hisamatsu T, Okamoto S, et al. Unique CD14t intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-g axis. J Clin Invest. 2008 ; 118 : 2269-80.
 
47) Rescigno M. Intestinal dendritic cells. Adv Immunol. 2010 ; 107 : 109-38.
PubMed
48) Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther. 2015 ; 97 : 22-8.
PubMed
49) Jovani M, Danese S. Vedolizumab for the treatment of IBD : a selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets. 2013 ; 14 : 1433-43.
PubMed
50) Danese S, Panes J. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases Gastroenterology. 2014 ; 147 : 981-9.
PubMed
51) Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547659 in ulcerative colitis : a randomised study. Gut. 2011 ; 60 : 1068-75.
PubMed
52) Sandborn WJ, Feagan BG, Wolf DC, et al ; TOUCHSTONE Study Group. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med. 2016 ; 374 : 1754-62.
 
53) 54. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4t lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease : Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996 ; 157 : 1261-70.
 
54) Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014 ; 14 : 329-42.
PubMed
55) Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 ; 13 : 715-25.
 
56) Teng MW, Bowman EP, McElwee JJ, et al. IL-12 and IL-23 cytokines : from discovery to targeted therapies for immunemediated inflammatory diseases. Nat Med. 2015 ; 21 : 719-29.
 
57) Feagan BG, Sandborn WJ, Gasink C, et al ; UNITIeIM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2016 ; 375 : 1946-60.
 
58) Hueber W, Sands BE, Lewitzky S, et al ; Secukinumab in Crohn's Disease Study Group. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease : unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012 ; 61 : 1693-700.
 
59) Weaver CT, Elson CO, Fouser LA, et al. The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin. Annu Rev Pathol. 2013 ; 8 : 477-512.
PubMed
60) Zhou L, Lopes JE, Chong MM, et al. TGF-b-induced Foxp3 inhibits TH17 cell differentiation by antagonizing RORgt function. Nature. 2008 ; 453 : 236-40.
 
61) Ghoreschi K, Laurence A, Yang XP, et al. Generation of pathogenic TH17 cells in the absence of TGF-b signalling. Nature. 2010 ; 467 : 967-71.
PubMed
62) Maloy KJ, Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011 ; 474 : 298-306.
PubMed
63) Himmel ME, Yao Y, Orban PC, et al. Regulatory T-cell therapy for inflammatory bowel disease : more questions than answers. Immunology. 2012 ; 136 : 115-22.
PubMed
64) Galien R. Janus kinases in inflammatory bowel disease : four kinases for multiple purposes. Pharmacol Rep. 2016 ; 68 : 789-96.
PubMed
65) O'Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway : impact on human disease and therapeutic intervention. Annu Rev Med. 2015 ; 66 : 311-28.
 
66) Sandborn WJ, Su C, Sands BE, et al ; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017 ; 376 : 1723-36.
PubMed

第4章 クローン病の治療

P.37 掲載の参考文献
1) Gasparetto M, Guariso G. Crohn's disease and growth deficiency in children and adolescents. World J Gastroenterol. 2014 ; 20 : 13219-33.
PubMed
2) Nielsen OH, Ainsworth M, Coskun M, et al. Management of Iron-Deficiency Anemia in Inflammatory Bowel Disease : A Systematic Review. Medicine (Baltimore). 2015 ; e963.
PubMed
3) Adams DW, Gurwara S, Silver HJ, et al. Sarcopenia Is Common in Overweight Patients with Inflammatory Bowel Disease and May Predict Need for Surgery. Inflamm Bowel Dis. 2017 ; 23 : 1182-4.
PubMed
4) Bryant RV, Ooi S, Schultz CG, et al. Low muscle mass and sarcopenia : common and predictive of osteopenia in inflammatory bowel disease. Aliment Pharmacol Ther. 2015 ; 41 : 895-906.
PubMed
5) 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究班」 (鈴木班) 平成30年度分担研究報告書 クローン病治療指針, 2019.
 
6) Duerksen DR, Nehra V, Bistrian BR, et al. Appropriate nutritional support in acute and complicated Crohn's disease. Nutrition. 1998 ; 14 : 462-5.
PubMed
7) Brennan GT, Ha I, Hogan C, et al. Does preoperative enteral or parenteral nutrition reduce postoperative complications in Crohn's disease patients : a metaanalysis. Eur J Gastroenterol Hepatol. 2018 ; 30 : 997-1002.
PubMed
8) Kaakoush NO, Day AS, Leach ST, et al. Effect of exclusive enteral nutrition on the microbiota of children with newly diagnosed Crohn's disease. Clin Transl Gastroenterol. 2015 ; 6 : e71.
PubMed
9) Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for induction of remission in Crohn's disease. Cochrane Database Syst Rev. 2007 ; 24 : CD000542.
 
10) Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014 ; 8 : 1179-207.
PubMed
11) Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease : A randomized-controlled trial. Aliment Pharmacol Ther. 2006 ; 24 : 1333-40.
PubMed
12) Wang H, Zuo L, Zhao J, et al. Impact of Preoperative Exclusive Enteral Nutrition on Postoperative Complications and Recurrence After Bowel Resection in Patients with Active Crohn's Disease. World J Surg. 2016 ; 40 : 1993-2000.
PubMed
13) Matsumoto T, Iida M, Kohgo Y, et al. Therapeutic efficacy of infliximab on active Crohn's disease under nutritional therapy. Scand J Gastroenterol. 2005 ; 40 : 1423-30.
PubMed
14) Tanaka T, Takahama K, Kimura T, et al. Effect of concurrent elemental diet on infliximab treatment for Crohn's disease. J Gastroenterol Hepatol. 2006 ; 21 : 1143-9.
PubMed
15) Yamamoto T, Nakahigashi M, Umegae S, et al. Prospective clinical trial : enteral nutrition during maintenance infliximab in Crohn's disease. J Gastroenterol. 2010 ; 45 : 24-9.
PubMed
16) Sazuka S, Katsuno T, Nakagawa T, et al. Concomitant use of enteral nutrition therapy is associated with sustained response to infliximab in patients with Crohn's disease. Eur J Clin Nutr. 2012 ; 66 : 1219-23.
PubMed
17) Hirai F, Ishihara H, Yada S, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn's disease in adults. Dig Dis Sci. 2013 ; 58 : 1329-34.
PubMed
18) Kamata N, Oshitani N, Watanabe K, et al. Efficacy of concomitant elemental diet therapy in scheduled infliximab therapy in patients with Crohn's disease to prevent loss of response. Dig Dis Sci. 2015 ; 60 : 1382-8.
PubMed
19) Nguyen DL, Palmer LB, Nguyen ET, et al. Specialized enteral nutrition therapy in Crohn's disease patients on maintenance infliximab therapy : a meta-analysis. Therap Adv Gastroenterol. 2015 ; 8 : 168-75.
PubMed
20) Sugita N, Watanabe K, Kamata N, et al. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease. J Gastroenterol Hepatol. 2018 ; 33 : 631-27.
PubMed
21) Hisamatsu T, Kunisaki R, Nakamura S, et al. Effect of elemental diet combined with infliximab dose escalation in patients with Crohn's disease with loss of response to infliximab : CERISIER trial. Intest Res. 2018 ; 16 : 494-8.
PubMed
22) Feagan, BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease : the EPIC Randomized Controlled Trials. JAMA. 2008 ; 299 : 1690-7.
PubMed
23) Ananthakrishnan AN, Khalili H, Konijeti GG, et al. A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology. 2013 ; 145 : 970-7.
PubMed
P.43 掲載の参考文献
1) Yamamoto-Furusho JK, Penaloza-Coronel A, Sanchez-Munoz F, et al. Peroxisome proliferator-actvated receptor gamma (PPARγ) expression is downregulated in patients with active ulcerative colitis. Inflamm Bowel Dis. 2011 ; 17 : 680-1.
 
2) Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med. 2005 ; 201 : 1205-15.
PubMed
3) Miller DK, Gillard JW, Vickers PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature. 1990 ; 343 : 278-81.
PubMed
4) Stevens C, Lipman M, Fabry S, et al. 5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells. J Pharmacol Exp Ther. 1995 ; 272 : 399-406.
 
5) Burress GC, Musch MW, Jurivich DA, et al. Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology. 1997 ; 113 : 1474-9.
PubMed
6) Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut. 1981 ; 22 : 642-7.
PubMed
7) Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis : a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009 ; 58 : 233-40.
PubMed
8) Lim WC, Wang Y, MacDonald JK, et al. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev. 2016 ; CD008870.
PubMed
9) Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease : a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004 ; 2 : 379-88.
PubMed
10) Coward S, Kuenzig ME, Hazlewood G, et al. Comparative effectiveness of mesalamin, sulfasalazine, corticosteroids, and budesonide for the induction of remission in crohn's disease : a bayesian network meta-analysis : republished. Inflamm Bowel Dis. 2017 ; 23 : E26-E37.
PubMed
11) Gordon M, Naidoo K, Thomas AG, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2011 ; CD008414.
PubMed
12) Rao SS, Cann PA, Holdsworth CD. Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine. Scand J Gastroenterol. 1987 ; 22 : 332-6.
PubMed
13) Cuffari C, Pierce D, Korczowski B, et al. Randomized clinical trial : pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis. Drug Des Devel Ther. 2016 ; 10 : 593-607.
PubMed
14) Taleban S, Colombel JF, Mohler MJ, et al. Inflammatory bowel disease and the elderly : A review. J Crohns Colitis. 2015 ; 9 : 507-15.
PubMed
P.47 掲載の参考文献
1) Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med. 1994 ; 331 : 842-5.
 
2) Campieri M, Ferguson A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997 ; 41 : 209-14.
 
3) 炎症性腸疾患 (IBD) 診療ガイドライン 2016. 日本消化器病学会編. 南江堂, 東京 ; 2016.
 
4) 鈴木康夫. 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」平成30年度 潰瘍性大腸炎・クローン病 診断基準・治療指針.
 
5) Summers RW, Switz DM, Sessions JT, Jr, et al. National Cooperative Crohn's Disease Study : results of drug treatment. Gastroenterology. 1979 ; 77 : 847-69.
PubMed
6) Malchow H, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS) : results of drug treatment. Gastroenterology. 1984 ; 86 : 249-66.
PubMed
7) Gionchetti P, Dignass A, Danese S, et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016 : Part 2 : Surgical Management and Special Situations. J Crohns Colitis. 2017 ; 11 : 135-49.
PubMed
P.53 掲載の参考文献
1) Zetterstrom R. G.B. Elion (1918-1999) and G.H. Hitchings (1905-1998) : breakthrough in the treatment of childhood leukaemia. Acta Paediatr. 2006 ; 95 : 898-900.
 
2) Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways : analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann NY Acad Sci. 2006 ; 1072 : 98-113.
PubMed
3) Roblin X, Oussalah A, Chevaux JB, et al. Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice : a worldwide survey of experts. Inflamm Bowel Dis. 2011 ; 17 : 2480-7.
PubMed
4) Ban H, Andoh A, Imaeda H, et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol. 2010 ; 45 : 1014-21.
PubMed
5) Yang SK, Hong M, Baek J, et al. A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet. 2010 ; 46 : 1017-20.
 
6) Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia. J Clin Oncol. 2015 ; 33 : 1235-42.
PubMed
7) Kakuta Y, Naito T, Onodera M, et al. NUDT15 R139C causes thiopurine-induced early severe hair loss and leukopenia in Japanese patients with IBD. Pharmacogenomics J. 2016 ; 16 : 280-5.
PubMed
8) Kakuta Y, Kawai Y, Okamoto D, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol. 2018 ; 53 : 1065-78.
PubMed
9) 鈴木康夫. 厚生労働科学研究費補助金 難治性疾患等政策研究事業「難治性炎症性腸管障害に関する調査研究」平成30年度潰瘍性大腸炎・クローン病 診断基準・治療指針.
 
10) Lowry PW, Franklin CL, Weaver AL, et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut. 2001 ; 49 : 656-64.
 
11) Gilissen LP, Bierau J, Derijks LJ, et al. The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Aliment Pharmacol Ther. 2005 ; 22 : 605-11.
PubMed
12) Blaker PA, Arenas-Hernandez M, Smith MA, et al. Mechanism of allopurinol induced TPMT inhibition. Biochem Pharmacol. 2013 ; 86 : 539-47.
PubMed
13) Sparrow MP, Hande SA, Friedman S, et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther. 2005 ; 22 : 441-6.
 
14) Nakase H, Motoya S, Matsumoto T, et al. Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease : a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017 ; 46 : 873-82.
PubMed
15) Boyapati RK, Torres J, Palmela C, et al. Withdrawal of immnosuppressant or biologic therapy for patients with quiescent Crohn's disease. Cochrane Database Syst Rev. 2018 ; 5 : CD012540.
PubMed
16) Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996 ; 347 : 215-9.
 
17) Lobel EZ, Korelitz BI, Xuereb MA, et al. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol. 2004 ; 99 : 462-5.
PubMed
18) Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease : a prospective observational cohort study. Lancet. 2009 ; 374 : 1617-25.
PubMed
19) Fukata N, Okazaki K, Omiya M, et al. Hematologic malignancies in the Japanese patients with inflammatory bowel disease. J Gastroenterol. 2014 ; 49 : 1299-306.
PubMed
P.63 掲載の参考文献
1) 医薬品インタビューフォーム レミケード(R) 点滴静注用 100, 2018年8月改訂 (第28版).
 
2) Thomas SS, Borazan N, Barroso N, et al. Comparative Immunogenicity of TNF Inhibitors : Impact on Clinical Efficacy and Tolerability in the Management of Autoimmune Diseases. A Systematic Review and Meta-Analysis. BioDrugs. 2015 ; 29 : 241-58.
PubMed
3) D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease : an open randomised trial. Lancet. 2008 ; 371 : 660-7.
PubMed
4) Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn's disease (REACT) : a cluster randomised controlled trial. Lancet. 2015 ; 386 : 1825-34.
PubMed
5) Papamichael K, Gils A, Rutgeerts P, et al. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD : evolution in the definition and management of primary nonresponse. Inflamm Bowel Dis. 2015 ; 21 : 182-97.
PubMed
6) Ding NS, Hart A, De Cruz P. Systematic review : predicting and optimising response to anti-TNF therapy in Crohn's disease-algorithm for practical management. Aliment Pharmacol Ther. 2016 ; 43 : 30-51.
PubMed
7) Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease : the ACCENT I randomised trial. Lancet. 2002 ; 359 : 1541-9.
PubMed
8) Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004 ; 350 : 876-85.
PubMed
9) Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology. 2009 ; 136 : 441-50. e1 ; quiz 716.
 
10) Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease : a review. Am J Gastroenterol. 2009 ; 104 : 760-7.
PubMed
11) Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010 ; 362 : 1383-95.
 
12) Hibi T, Sakuraba A, Watanabe M, et al. Retrieval of serum infliximab level by shortening the maintenance infusion interval is correlated with clinical efficacy in Crohn's disease. Inflamm Bowel Dis. 2012 ; 18 : 1480-7.
PubMed
13) Feuerstein JD, Nguyen GC, Kupfer SS, et al. American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease. Gastroenterology. 2017 ; 153 : 827-34.
PubMed
14) Cheifetz A, Mayer L. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mt Sinai J Med. 2005 ; 72 : 250-6.
PubMed
15) Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008 ; 67 : 189-94.
PubMed
16) Parakkal D, Sifuentes H, Semer R, et al. Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy : expanding the groups at risk. Eur J Gastroenterol Hepatol. 2011 ; 23 : 1150-6.
 
17) Bernheim O, Colombel JF, Ullman TA, et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut. 2013 ; 62 : 1523-8.
PubMed
18) Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease. J Crohns Colitis. 2012 ; 6 : 160-73.
PubMed
19) Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease : a systematic review. Am J Gastroenterol. 2011 ; 106 : 674-84.
PubMed
20) Matsumoto T, Motoya S, Watanabe K, et al. Adalimumab Monotherapy and a Combination with Azathioprine for Crohn's Disease : A Prospective, Randomized Trial. J Crohns Colitis. 2016 ; 10 : 1259-66.
 
21) Tanaka H, Kamata N, Yamada A, et al. Long-term retention of adalimumab treatment and associated prognostic factors for 1189 patients with Crohn's disease. J Gastroenterol Hepatol. 2018 ; 33 : 1031-8.
PubMed
22) Nakase H, Motoya S, Matsumoto, et al : Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease : a subanalysis of the DIAMOND trial. Aliment Pharmacol Ther. 2017 ; 46 : 873-82.
PubMed
23) Watanabe K, Matsumoto T, Hisamatsu T, et al. Clinical and Pharmacokinetic Factors Associated With Adalimumab-Induced Mucosal Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2018 ; 16 : 542-9.
PubMed
24) Kakuta Y, Kawai Y, Okamoto D, et al. NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease : a multicenter study. J Gastroenterol. 2018 ; 53 : 1065-78.
PubMed
25) Hisamatsu T, Kato S, Kunisaki R, et al. Withdrawal of thiopurines in Crohn's disease treated with scheduled adalimumab maintenance : a prospective randomised clinical trial (DIAMOND2). J Gastroenterol. 2019 Apr 30. doi : 10.1007/s00535-019-01582-w.
 
P.67 掲載の参考文献
1) Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N Engl J Med. 2016 ; 375 : 1946-60.
PubMed
2) Sandborn WJ, Rutgeerts P, Gasink C, et al. Longterm efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. Aliment Pharmacol Ther. 2018 ; 48 : 65-77.
 
3) Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis : first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018 ; 48 : 394-409.
PubMed
P.71 掲載の参考文献
1) Iwata M, Hirakiyama A, Eshima Y, et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004 ; 21 : 527-38.
 
2) Sandborn WJ, Feagan BG, Rutgeerts P, et al ; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013 ; 369 : 711-21.
 
3) Sands BE, Feagan BG, Rutgeerts P, et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014 ; 147 : 618-27.e3.
 
4) Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017 ; 66 : 839-51.
PubMed
P.75 掲載の参考文献
1) Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment : a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016 ; 310 : G155-62.
PubMed
2) Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016 ; 12 : 25-36.
PubMed
3) Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2017 ; 376 : 1723-36.
PubMed
4) Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn's disease. Clin Gastroenterol Hepatol. 2014 ; 12 : 1485-93. e2.
 
5) Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn's disease : results of two phase IIb randomised placebo-controlled trials. Gut. 2017 ; 66 : 1049-59.
PubMed
6) Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-tosevere Crohn's disease treated with filgotinib (the FITZROY study) : results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017 ; 389 : 266-75.
 
7) Sandborn WJ, Feagan BG, Panes J, et al. Safety and Efficacy of ABT-494 (Upadacitinib), an Oral Jak1 Inhibitor, as Induction Therapy in Patients with Crohn's Disease : Results from Celest. Gastroenterology. 2017 ; 152 (Supplement 1) ; S1308-S1309.
 

書評

最近チェックした商品履歴

Loading...